英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
contemptus查看　contemptus　在百度字典中的解释百度英翻中〔查看〕
contemptus查看　contemptus　在Google字典中的解释Google英翻中〔查看〕
contemptus查看　contemptus　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Treating Squamous Cell Carcinoma | Squamous Cell Cancer . . .
    Treating advanced squamous cell cancers Different types of treatments might be used for SCCs that have spread beyond the skin Lymph node dissection: Removing regional (nearby) lymph nodes might be recommended for some SCCs that are very large or have grown deeply into the skin, as well as if the lymph nodes feel enlarged and or hard
  • Cemiplimab-rwlc - NCI - National Cancer Institute
    Cemiplimab-rwlc is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy) It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells It works by keeping cancer cells from suppressing the immune system This allows the immune system to attack and kill the cancer cells
  • LIBTAYO® Full Prescribing Information | Regeneron
    1 3 Non-Small Cell Lung Cancer LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side . . .
    This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment
  • label - accessdata. fda. gov
    1 3 Non-Small Cell Lung Cancer LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • Libtayo (cemiplimab) dosing, indications, interactions . . .
    Medscape - Cutaneous squamous cell carcinoma and basal cell carcinoma dosing for Libtayo (cemiplimab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost information
  • Cemiplimab (Libtayo®) - ChemoExperts
    Treatment Name: Cemiplimab (Libtayo®) Cemiplimab (Libtayo®) is an Immunotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does cemiplimab work? Cemiplimab is designed to block the signals that tumor cells use to suppress the immune system allowing the immune system to attack the lung cancer cells Goals of therapy:
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Patient Resources for LIBTAYO® (cemiplimab-rwlc) | Advanced NSCLC
    LIBTAYO resources Get more information about LIBTAYO and how it may be an appropriate treatment option for your advanced NSCLC
  • Cemiplimab (Libtayo Regeneron) - Guidelines+ Monographs
    Libtayo is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC), locally advanced or metastatic basal cell carcinoma (laBCC or mBCC), and non-small cell lung cancer (NSCLC) It was initially approved in 2018





中文字典-英文字典  2005-2009